We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia (BAITP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05446831
Recruitment Status : Recruiting
First Posted : July 7, 2022
Last Update Posted : September 28, 2022
Information provided by (Responsible Party):
Xiao Hui Zhang, Peking University People's Hospital

Brief Summary:
Single-arm, open-label, single-center study to evaluate the efficacy and safety of baricitinib for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

Condition or disease Intervention/treatment Phase
ITP Immune Thrombocytopenia Drug: Baricitinib Phase 2

Detailed Description:
The investigators are undertaking a prospective trial of 20 adults with ITP in China. Baricitinib is administered as 4 mg po. daily. Safety outcomes and efficacy outcomes are assessed on scheduled study visits (primary endpoint defined as durable response at 6-month follow-up).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia: A Single-arm, Open-label Phase II Study
Actual Study Start Date : July 13, 2022
Estimated Primary Completion Date : June 1, 2023
Estimated Study Completion Date : December 1, 2023

Arm Intervention/treatment
Experimental: Baricitinib
Oral baricitinib was given at a dose of 4 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
Drug: Baricitinib
Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.

Primary Outcome Measures :
  1. Durable response [ Time Frame: 6 months ]
    The maintenance of a platelet count ≥30,000/μL, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up.

Secondary Outcome Measures :
  1. Complete response (CR) [ Time Frame: 1 month ]
    Complete response (CR) was defined as a platelet count over 100,000/μL and absence of bleeding.

  2. Response (R) [ Time Frame: 1 month ]
    Response (R) as a platelet count over 30,000/μL and at least 2-fold increase of the baseline count and absence of bleeding.

  3. Time to response [ Time Frame: 6 months ]
    The time from starting treatment to time of achievement of CR or R.

  4. Duration of response [ Time Frame: 6 months ]
    Duration of response at 6-month follow up.

  5. Early response [ Time Frame: 7 days ]
    Achievement of CR or R at day 7

  6. Initial response [ Time Frame: 28 days ]
    Achievement of CR or R at day 28

  7. Bleeding events [ Time Frame: From the start of study treatment (Day 1) to the end of week 24 ]
    Clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale.

  8. Health-related quality of life (HRQoL) [ Time Frame: From the start of study treatment (Day 1) to the end of week 24 ]
    ITP-PAQ is used to assess the Health Related Quality of Life (HRQoL) before and after treatment.

  9. Adverse events [ Time Frame: From the start of study treatment (Day 1) to the end of week 24 ]
    Adverse events (AEs) are reported and graded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia
  2. Patients with chronic low platelet count (<30,000/μL) for 6 months who have failed at least one treatment for chronic low platelet count
  3. Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation
  4. Patients with a platelet count <30,000/μL or a platelet count <50,000/μL with clinically significant bleeding symptoms at the enrollment
  5. Over 18 years old
  6. Willing and able to provide written informed consent, and agreeable to the schedule of assessment

Exclusion Criteria:

  1. Secondary immune thrombocytopenia (e.g. patients with HIV, HCV, Helicobacter pylori infection or patients with confirmed autoimmune disease)
  2. Active or a history of malignancy
  3. Pregnancy or lactation
  4. Current or recent (<4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection
  5. A history of symptomatic herpes zoster infection within 12 weeks prior to screening
  6. Active or chronic viral infection from hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
  7. Have evidence of active tuberculosis (TB), or have previously had evidence of active TB and did not receive appropriate and documented treatment, or have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB
  8. Have experienced a clinically significant thrombotic event within 24 weeks of screening or are on anticoagulants and in the opinion of the investigator are not well controlled
  9. Myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure
  10. A history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data
  11. Any of the following specific abnormalities on screening laboratory tests:

1) ALT or AST >2 x ULN, or total bilirubin ≥1.5 x ULN 2) hemoglobin <9 g/dL, or total white blood cell (WBC) count <2,500/µL, or neutropenia (absolute neutrophil count <1,200/µL), or lymphopenia (lymphocyte count <750/µL) 3) eGFR <50 mL/min/1.73 m^2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05446831

Layout table for location contacts
Contact: Xiaohui Zhang, MD +8613522338836 zhangxh100@sina.com
Contact: Peng Zhao, MD +8618810323668 zpeng702@163.com

Layout table for location information
China, Beijing
Peking University Insititute of Hematology, Peking University People's Hospital Recruiting
Beijing, Beijing, China, 100010
Contact: Xiaohui Zhang, MD    +8613522338836    zhangxh100@sina.com   
Contact: Peng Zhao, MD    +8618810323668    zpeng702@163.com   
Principal Investigator: Xiaohui Zhang, MD         
Sponsors and Collaborators
Peking University People's Hospital
Layout table for investigator information
Principal Investigator: Xiaohui Zhang, MD Peking University People's Hospital
Layout table for additonal information
Responsible Party: Xiao Hui Zhang, Vice president of Peking Univeristy Institute of Hematology, Peking University People's Hospital
ClinicalTrials.gov Identifier: NCT05446831    
Other Study ID Numbers: PKU-ITP2207
First Posted: July 7, 2022    Key Record Dates
Last Update Posted: September 28, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura, Thrombocytopenic, Idiopathic
Pathologic Processes
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Skin Manifestations